ATP6V0D1

ATP6V0D1 Full Name

ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1

ATP6V0D1 Introduction

ATP6V0D1 is a highly conserved and critical structural component of the vacuolar-type H+-ATPase (V-ATPase) complex. The V-ATPase functions as a massive, ATP-dependent molecular motor that actively pumps protons across cellular membranes to acidify intracellular compartments such as lysosomes, endosomes, and the Golgi apparatus. Within this multi-subunit complex, ATP6V0D1 serves as subunit d1 of the integral membrane V0 sector. Its primary biological role is to act as an essential physical and functional "bridge" that couples the ATP-hydrolyzing V1 domain to the proton-translocating V0 domain. This structural coupling enables the efficient, continuous pumping of protons against their concentration gradient. The resulting acidic microenvironment is absolutely vital for driving lysosomal degradation, facilitating autophagosome-lysosome fusion, recycling cellular receptors, and maintaining the overarching metabolic homeostasis of the cell through the autophagy pathway.

Figure 1. The assembly regulation of V-ATPase in mammalian cells. (Source: Chen YY, et al. 2025)

Clinically, the dysregulation of ATP6V0D1 is heavily implicated in tumor progression and chemoresistance across multiple highly aggressive malignancies. Cancer cells are notoriously dependent on elevated V-ATPase activity to clear out toxic metabolic byproducts and deliberately acidify the extracellular tumor microenvironment. This pathological acidification actively promotes tumor cell invasion, tissue metastasis, and immune evasion. Furthermore, recent molecular studies have identified ATP6V0D1 as a critical driver of multidrug resistance in cancers such as neuroblastoma and osteosarcoma. By upregulating ATP6V0D1, chemoresistant cancer cells dramatically enhance their lysosomal capacity and autophagic survival mechanisms. This allows them to effectively sequester, trap, and degrade chemotherapeutic drugs inside highly acidic lysosomes before the drugs can reach the nucleus to induce cell death.

Beyond oncology, the physiological reliance on ATP6V0D1-mediated endosomal acidification presents a unique vulnerability during viral pathogenesis. Numerous enveloped viruses, including SARS-CoV-2 and influenza, strictly require a highly acidic endosomal microenvironment to trigger viral membrane fusion and successfully release their viral genome into the host cytoplasm. Consequently, the targeted pharmacological inhibition or genetic silencing of ATP6V0D1 not only sensitizes drug-resistant tumors but also serves as a potent strategy for broad-spectrum antiviral interventions, highlighting this subunit as a highly valuable therapeutic target in modern precision medicine.

Alternate Names for ATP6V0D1

ATP6V0D1; ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1; ATP6D, ATPase, H+ transporting, lysosomal (vacuolar proton pump), member D; ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d isoform 1; ATPase, H+ transporting, lysosomal 38kDa, V0 subunit D1; V-type proton ATPase subunit d 1; ATP6DV; P39; VATX; Vma6

• 1. Chen YY, et al. The Emerging Roles of Vacuolar-Type ATPase-Dependent Lysosomal Acidification in Cardiovascular Disease. Biomolecules. 2025 Apr 3;15(4):525.
  2. Rychla M, et al. The Role of V-ATPase ATP6V0D1 Subunit in Chemoresistance and Ellipticine-Induced Cytoplasmic Vacuolation in Neuroblastoma Cells. Mol Cell Oncol. 2025 Jun 17;12(1):2518774.